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MaOBJECTIVES This study aimed to investigate the independent and joint associations between family history of
myocardial infarction (FH) and coronary artery calciﬁcation (CAC) with incident coronary heart disease (CHD).
BACKGROUND FH and CAC are associated with each other and with incident CHD. It is not known whether FH retains
its predictive value after CAC results are accounted for.
METHODS Among 2,390 participants without cardiovascular disease enrolled in the Dallas Heart Study, we assessed FH
(myocardial infarction in a ﬁrst-degree relative) and prevalent CAC by electron-beam computed tomography. The primary
outcome, a composite of CHD-related death, myocardial infarction, and percutaneous or surgical coronary revasculari-
zation, was assessed over a mean follow-up of 8.0  1.2 years. The individual and joint associations with the CHD
composite outcome were determined for FH and CAC.
RESULTS The mean age of the population was 44  9 years; 32% had FH and 47% had a CAC score of 0. In multivariate
models adjusted for traditional risk factors, FH was independently associated with CHD (adjusted hazard ratio: 2.6; 95%
conﬁdence interval: 1.6 to 4.2; p < 0.001). Further adjustment for prevalent CAC did not diminish this association
(adjusted hazard ratio: 2.6; 95% conﬁdence interval: 1.6 to 4.2; p < 0.001). FH and CAC were additive: CHD event rates in
those with both FH and CAC were 8.8% vs. 3.3% in those with prevalent CAC alone (p < 0.001). CHD rates were 1.9% in
those with FH alone compared with 0.4% in those with neither FH nor CAC (p < 0.017). Among subjects without CAC, FH
characterized a group with a more unfavorable cardiometabolic proﬁle.
CONCLUSIONS FH provided prognostic information that was independent of and additive to CAC. Among those with
CAC, FH identiﬁed subjects at particularly high short-term risk, and, among those without it, selected a group with an
adverse risk-factor proﬁle. (J Am Coll Cardiol Img 2014;7:679–86) © 2014 by the American College of Cardiology
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TRF = traditional risk factor(s)
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680most powerful predictors of incident coro-
nary heart disease (CHD) (6). Contrary to
most other novel biomarkers, CAC signiﬁ-
cantly improves the c statistic and net
reclassiﬁcation when added to traditional
risk factor (TRF) models (7).SEE PAGE 687Patients with FH are often referred for
CAC scanning and have an increased preva-
lence of CAC (8,9); yet, the signiﬁcance of FHafter CAC values are known is unclear. One possibility
is that heritable factors reﬂected in FH will already be
captured as coronary plaque and calciﬁcation by
adulthood, such that FH provides no additional pre-
dictive information beyond CAC values. Alterna-
tively, FH and CAC may be additive in predictive
value, just as FH has been shown to be additive with
other risk factors (8). Thus, in a large, population-
based study, we sought to determine the indepen-
dent and joint effects of FH and CAC on the risk for
CHD events.
METHODS
STUDY SAMPLE. The DHS (Dallas Heart Study) is
a multiethnic, probability-based, population cohort
study in adults in Dallas County, Texas,with deliberate
oversampling of African Americans. Detailed methods
of DHS phase 1 (DHS-1) have been described previously
(10). All subjects provided written informed consent,
and the study protocol was approved by the institu-
tional review board of the University of Texas South-
western Medical Center. Brieﬂy, between 2000 and
2002, 2,971 participants completed the 3 visits of
DHS-1, including a detailed in-home survey, laboratory
testing, and multiple imaging studies, as described
subsequently. Of 2,971 patients, 228 did not have an
interpretable CAC scan, 74 reported a history of car-
diovascular disease, 88 hadmissing covariates, and 191
had incomplete follow-up for nonfatal endpoints
(Online Fig. 1). The ﬁnal study population comprised
2,390 participants free of cardiovascular disease and
followed up for fatal and nonfatal CHD events.
DEFINITIONS. Race/ethnicity, history of cardiovas-
cular disease, individual medication usage, family
history, and smoking status were self-reported.
Detailed deﬁnitions of the variables hypertension,
metabolic syndrome, and diabetes in the DHS have
been previously published (11). FH was deﬁned as any
ﬁrst-degree relative with a history of myocardial
infarction. Family history of premature CHD was
deﬁned as myocardial infarction occurring before the
age of 50 years in a ﬁrst-degree male relative or beforethe age of 55 years in a ﬁrst-degree female relative, as
predetermined in the original DHS questionnaire (8).
Given the small number of subjects with premature
FH, we used the more inclusive deﬁnition of any FH
for the primary analyses. As part of our subgroup
analysis, participants were stratiﬁed using pre-
speciﬁed age cutoffs of 45 years of age in men and
55 years in women (12). This deﬁnition was chosen on
the basis of prior reports from the DHS, in which FH
was a stronger predictor of CAC among younger par-
ticipants (8).
MEASUREMENTS. Analytical methods for the bio-
markers reported in this study have been previously
described, including high-sensitivity C-reactive pro-
tein (13), highly sensitive troponin T (14), N-terminal
pro-brain natriuretic peptide (15), and lipoprotein
assessment (16). Glomerular ﬁltration rate was calcu-
lated using the Modiﬁcation of Diet in Renal Disease
formula (17). Homeostasis model assessment of
insulin resistance was calculated using the following
formula (18):
fasting insulin ðmIU=mlÞfasting glucose ðmmol=lÞ=22:5
Electron-beam CT measurements of CAC were per-
formed in duplicate, 1 to 2 min apart, on an Imatron
150 XP scanner (Imatron Inc., San Bruno, California).
The 2 CAC scores were determined using the Agatston
method and then averaged (19). Dual-energy x-ray
absorptiometry (Delphi scanner, Hologic, and Dis-
covery software version 12.2, Bedford, Massachusetts)
was used to measure total body fat (20). Cardiac and
aortic magnetic resonance imaging measurements
were performed using a 1.5-T magnetic resonance
imaging system (Intera, Philips Medical Systems, Best,
the Netherlands). Left ventricular mass, aortic wall
thickness, and aortic compliance were calculated
according to previously published methods (14,21).
CLINICAL OUTCOMES. The primary outcome was a
composite of CHD-related death, myocardial infarc-
tion, and/or coronary revascularization. All re-
vascularization events (coronary artery bypass
surgery and percutaneous revascularization) occur-
ring within the ﬁrst 3 months of CAC scanning were
excluded from the analyses as they could have been
driven by the CAC test result. Death events were
ascertained through December 31, 2009, in all sub-
jects in the DHS, using the National Death Index (14).
Deaths were classiﬁed as secondary to CHD if they
included International Statistical Classiﬁcation of
Diseases, 10th Revision codes I20 to I25. Subjects
were contacted annually to participate in a detailed
health survey regarding interval nonfatal cardiovas-
cular events. In addition, subjects who provided
TABLE 1 Baseline Characteristics of Study Patients, Stratiﬁed
by Family History of MI
No Family
History of MI
(n ¼ 1,624)
Positive Family
History of MI
(n ¼ 766) p Value
Demographic/clinical
Age, yrs 43 (36  50) 48 (41  56) <0.001
Female 54 62 <0.001
Race
Black 48 49 0.599
White 32 40 <0.001
Hispanic 18 10 <0.001
Other 2 1 0.044
BMI, kg/m2 29 (25–33) 30 (26–35) 0.001
Laboratory analysis
TC, mg/dl 178 (154–204) 183 (162–209) <0.001
LDL-C, mg/dl 105 (82–128) 110 (86–132) 0.013
HDL-C, mg/dl 48 (40–58) 48 (41–58) 0.241
Triglycerides, mg/dl 95 (67–142) 102 (72–153) 0.003
GFR, ml/min 98 (86–111) 94 (83–108) <0.001
hs-CRP, mg/l 2.5 (1.1–5.7) 3.1 (1.3–7.5) <0.001
Risk factor
Metabolic syndrome 30 43 <0.001
Hypertension 28 42 <0.001
Smoker 26 27 0.804
Diabetes 8 13 <0.001
FRS
<6 82 76 0.002
6–20 16 20 0.027
>20 2 4 0.019
CAC score 0.5 (0.0–3.1) 1.0 (0.0–14.1) <0.001
0 49.7 40.7 <0.001
>0–10 33.9 31.6 0.264
>10–100 10.0 15.8 <0.001
>100–400 4.7 8.5 0.001
>400 1.7 3.4 0.011
Treatment history
Antihypertensive drug 16 30 <0.001
Aspirin 6 10 0.001
Statin 5 9 <0.001
Values are mean  SD, %, or median (interquartile range).
BMI ¼ body mass index; CAC ¼ coronary artery calciﬁcation; FRS ¼ Framingham risk score;
GFR ¼ glomerular ﬁltration rate; HDL-C ¼ high-density lipoprotein cholesterol; hs-CRP ¼
high-sensitivity C-reactive protein; LDL ¼ low-density lipoprotein cholesterol; MI ¼ myocardial
infarction; TC ¼ total cholesterol.
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681consent were tracked for hospital admissions using the
Dallas Fort Worth Hospital Council Data Initiative
database, which includes hospital admission data for
70 of 72 hospitals in the Dallas/Fort Worth metroplex.
Greater than 90% of subjects from the initial imaging
visit were followed up for nonfatal events with these
data sources. Primary records were requested for all
suspected cardiovascular events, and these events
were each adjudicated separately by 2 cardiologists
blinded to CAC assessment and all study variables.
STATISTICAL ANALYSIS. Baseline demographic and
clinical variables were compared between partici-
pants with and without FH using the chi-square test
for categorical variables and Wilcoxon rank sum test
for continuous variables. Kaplan-Meier cumulative-
events curves were constructed for CHD events and
compared using log-rank statistics. Cox proportional
hazard analysis was used to assess the association
between FH and incident CHD in univariate and
multivariate models adjusted for age, sex, systolic
blood pressure, presence of diabetes, total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C),
smoking status, and use of antihypertensive drugs or
statins. For the primary analysis, CAC was added to
the multivariate models as a categorical variable (0
vs. >0). Sensitivity analyses were performed with
CAC #10 versus >10, as a continuous variable (ln
[CAC þ 1]), and as an ordinal variable (0, >0 to 10, >10
to 100, >100 to 400, and >400). The proportional
hazards assumption was tested by Schoenfeld re-
siduals. The interaction between FH and CAC was
tested by adding a multiplicative variable to the fully-
adjusted Cox model. Improvement in discrimination
was assessed by comparing the c statistics in models
with and without FH and CAC, using the Harrell c
statistic, and signiﬁcance was determined using
bootstrapping. Category-free or continuous net
reclassiﬁcation improvement (NRI) was also calcu-
lated by bootstrapping (22). We divided our cohort
into 4 mutually exclusive groups on the basis of the
presence or absence of CAC and FH. Traditional and
novel markers were compared among those 4 groups.
Because, after stratiﬁcation by CAC, participants with
and without FH had signiﬁcant age and sex differ-
ences, logistic and linear regression models adjusted
for age and sex were used for this analysis. All sta-
tistical analyses were performed using the SAS soft-
ware package version 9.2 (SAS Institute Inc., Cary,
North Carolina).
RESULTS
The characteristics of the study population stratiﬁed
by the presence or absence of FH are displayedin Table 1. The overall mean age was 44  9 years,
56% of subjects were female, and 48% were African
American. Most participants were classiﬁed as low
risk (<6% 10-year risk) on the basis of the Framing-
ham risk score (80%), and 47% had a CAC score of 0.
FH at any age was reported by 32% of patients, and
premature FH was reported by 10%. Participants
with a positive FH tended to be older, were more
often female, had higher prevalences of hyperten-
sion and diabetes, and had a more unfavorable lipid
proﬁle.
FIGURE 1 Cumulative Incidence of CHD Events
Patients are stratiﬁed by family history of myocardial infarction (FH) and
presence (coronary artery calciﬁcation [CAC] score: >0) or absence (CAC
score: 0) of coronary artery calciﬁcation. CHD ¼ coronary heart disease.
TABLE 2 Hazard Ratios for Incident CHD on the Basis of
Family History of MI
Family History of MI
Premature
Family History of MI
HR (95% CI) p Value HR (95% CI) p Value
Model 1* 3.3 (2.1–5.2) <0.001 3.0 (1.8–5.1) <0.001
Model 2† 2.6 (1.6–4.2) <0.001 2.9 (1.7–5.0) <0.001
Model 3‡ 2.6 (1.6–4.2) <0.001 2.9 (1.7–5.0) <0.001
*Univariate analysis. †Adjusted for age, sex, systolic blood pressure, presence
of diabetes, TC, HDL-C, smoking status, and antihypertensive drug and statin use.
‡Adjusted for age, sex, systolic blood pressure, presence of diabetes, TC, HDL-C,
smoking status, antihypertensive drug and statin use, and CAC score.
CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio; other
abbreviations as in Table 1.
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682A total of 76 ﬁrst CHD events occurred over a mean
follow-up of 8  1.2 years (CHD-related death: 17;
nonfatal myocardial infarction: 38; percutaneous
coronary revascularization: 16; and coronary bypass
surgery: 5). Coronary event rates in those with both
FH and CAC were 8.8% versus 3.3% in those with
prevalent CAC alone (p < 0.001). Among those
without CAC, CHD rates were 1.9% in those with
FH compared with 0.4% in those without FH
(p < 0.017) (Fig. 1). In univariate models, FH carried a
hazard ratio (HR) of 3.3 (95% conﬁdence interval (CI):
2.1 to 5.2; p < 0.001) (Table 2). In multivariate models
adjusted for TRF, FH remained signiﬁcantly associ-
ated with CHD (HRadj: 2.6; 95% CI: 1.6 to 4.2; p <
0.001). Further adjustment for CAC did not diminish
this association (HRadj: 2.6; 95% CI: 1.6 to 4.2; p <
0.001). Other independent predictors of CHD in the
fully-adjusted model were age, male sex, diabetes,
TC, smoking, use of antihypertensive drugs, and
CAC. In stratiﬁed analyses, FH was independently
associated with CHD events among those with CAC
(HRadj: 2.5; 95% CI: 1.5 to 4.2). Among those without
CAC, only 9 CHD events were observed, with a trend
toward higher CHD event rates among those with FH
(HRadj: 3.8; 95% CI: 0.9 to 16.3; p ¼ 0.07 in the fully-
adjusted model). No signiﬁcant interaction between
FH and CAC was detected (p ¼ 0.394).
Replacing FH with premature FH yielded similar
ﬁndings (HRadj: 2.9; 95% CI: 1.7 to 5.0; p < 0.001
in the fully-adjusted model). When CAC was
modeled as a continuous, ordinal, or categorical
variable using the cutoff of 10, results were also notsigniﬁcantly different, and the independent associ-
ation between FH and CHD was maintained (Online
Table 1).
The addition of FH to a model with TRF and CAC
modestly improved the c statistic (from 0.86 to
0.87; p ¼ 0.037) and resulted in signiﬁcant correct
reclassiﬁcation (category-free NRI ¼ 0.55; 95% CI:
0.27 to 0.83; p < 0.001). Discrimination measure-
ments for premature FH were virtually the same as
for any FH (c statistic: 0.87).
Among participants with and without CAC, those
with FH were older (mean age: 51 years vs. 46 years
[p < 0.001] and 44 years vs. 40 years [p < 0.001],
respectively), with a higher proportion of women
(55% vs. 46% [p < 0.001] and 69% vs. 62% [p ¼ 0.037],
respectively). After adjustment for age and sex,
among those with CAC, FH was associated only with
hypertension and aortic wall thickness (Table 3).
Among those without CAC, however, FH was associ-
ated with hypertension, diabetes, and metabolic
syndrome, as well as higher triglycerides, total fat
mass, and left ventricular mass (Table 3).
Among young participants, FH was associated
with a higher fully-adjusted HR of CHD (5.1; 95% CI:
1.7 to 15.0) compared with that in older participants
(HRadj: 2.0; 95% CI: 1.1 to 3.6; p ¼ 0.007) (Fig. 2). Point
estimates were numerically higher in participants
with 0 or 1 versus 2 or more risk factors (HRadj:
3.2 [95% CI: 1.5 to 7.1] vs. 2.0 [95% CI: 1.1 to 3.7]), but
the p value for interaction was not signiﬁcant (0.07).
The association between FH and CHD was signiﬁcant
in the subgroups with low (<6%) and intermediate
(6% to 20%) Framingham risk scores (HRadj: 2.4 [95%
CI: 1.0 to 5.7; p ¼ 0.049] and 2.3 [95% CI: 1.2 to 4.6;
p ¼ 0.015], respectively, in the fully-adjusted model).
In the small subgroup with high Framingham risk
(>20%), only 11 events occurred, yet there was a trend
toward higher CHD risk among those with FH (HRadj:
6.1; 95% CI: 0.9 to 37.4; p ¼ 0.052 in the fully-adjusted
TABLE 3 Phenotypic Features Associated With Family History of MI, Stratiﬁed by the Presence or Absence of CAC
CAC Score 0
(n ¼ 1,119)
CAC Score >0
(n ¼ 1,271)
Logistic Regression OR (95% CI) p Value OR (95% CI) p Value
Smoker 1.01 (0.74 to 1.38) 0.952 1.14 (0.87 to 1.48) 0.344
Hypertension 1.51 (1.08 to 2.10) 0.015 1.29 (1.00 to 1.66) 0.048
Statin 1.88 (0.97 to 3.64) 0.062 1.07 (0.70 to 1.64) 0.752
Aspirin 1.65 (1.00 to 2.72) 0.051 1.15 (0.75 to 1.76) 0.516
Diabetes 2.15 (1.17 to 3.96) 0.014 1.14 (0.82 to 1.58) 0.437
Metabolic syndrome 1.70 (1.25 to 2.32) 0.001 1.25 (0.99 to 1.59) 0.066
Black race 0.91 (0.69 to 1.20) 0.505 0.95 (0.75 to 1.21) 0.693
Nonblack race 1.10 (0.84 to 1.44) 0.505 1.05 (0.83 to 1.34) 0.693
Linear Regression Beta (95% CI) p Value Beta (95% CI) p Value
LDL-C 1.24 (–3.25 to 5.74) 0.587 3.61 (–0.62 to 7.85) 0.095
HDL-C –1.48 (–3.48 to 0.51) 0.146 –0.3 (–1.82 to 1.21) 0.697
Triglycerides 19.56 (8.45 to 30.67) <0.001 –9.03 (–22.89 to 4.83) 0.201
BMI 0.67 (0.00 to 1.35) 0.051 0.48 (–0.24 to 1.21) 0.187
Total fat mass 1.82 (0.69 to 2.96) 0.002 0.73 (–0.49 to 1.95) 0.238
GFR –0.04 (–2.80 to 2.71) 0.975 –1.34 (–4.03 to 1.36) 0.331
Cystatin-C –0.01 (–0.04 to 0.02) 0.600 0.00 (–0.03 to 0.03) 0.890
HOMA-IR 0.32 (–0.09 to 0.73) 0.132 0.18 (–0.37 to 0.72) 0.531
LV mass 4.87 (1.12 to 8.61) 0.011 1.89 (–3.03 to 6.82) 0.451
LV ejection fraction –0.26 (–1.16 to 0.63) 0.563 –0.83 (–1.80 to 0.14) 0.093
Aortic wall thickness 0.01 (–0.03 to 0.04) 0.739 0.04 (0.00 to 0.08) 0.037
Aortic compliance –0.83 (–2.22 to 0.56) 0.239 –0.52 (–1.75 to 0.71) 0.407
hs-CRP 0.57 (–0.02 to 1.16) 0.057 0.23 (–0.42 to 0.88) 0.491
NT-proBNP –6.76 (–29.96 to 16.44) 0.568 –23.54 (–86.74 to 39.65) 0.465
hs-TnT –0.14 (–0.60 to 0.32) 0.555 –0.15 (–1.02 to 0.71) 0.732
Logistic and linear regression models adjusted for age and sex.
HOMA-IR ¼ homeostasis model assessment of insulin resistance; hs-TnT ¼ highly sensitive troponin T; LV ¼ left ventricular; NT-proBNP ¼ N-terminal pro-brain natriuretic
peptide; OR ¼ odds ratio; other abbreviations as in Table 1.
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683model). No interaction was noted between FH and
Framingham risk score (p ¼ 0.480).
DISCUSSION
In a large, population-based cohort, we evaluated the
joint effects of FH and CAC on clinical CHD events
and report several relevant ﬁndings. First, FH was
independently associated with incident CHD, and this
association was not attenuated after CAC was
accounted for. Second, patients with both FH and
CAC were at higher CHD risk than were those with
each of these characteristics in isolation. Among
those without CAC, although overall event rates were
low, CHD risk was also higher in patients with FH.
These ﬁndings have important implications for the
interpretation of FH in the context of known CAC
values and suggest that knowledge of FH provides
additional relevant information.
Although FH has been shown to predict prevalent
CAC as well as progression of CAC in multiple pop-
ulations (8,23,24), few data are available integratingFH and CAC as predictors of future events. In an
analysis of the Family Heart Study, Hopkins et al. (25)
followed up a cohort for approximately 8 years and
performed CAC scanning at the last examination.
They then evaluated the cross-sectional association
of CAC with prevalent CHD at the end of this interval.
They reported that FH remained associated with CHD
after adjusting for CAC. However, because partici-
pants with and without incident CHD were scanned at
the last visit, it is possible that the clinical events
themselves affected coronary calciﬁcation through
subsequent revascularization or plaque rupture itself.
Thus, to our knowledge, this is the ﬁrst study to
formally test the relationship between FH and CAC
on clinical outcomes in a prospective, population-
based cohort.
The absence of signiﬁcant attenuation of the as-
sociation between FH and CHD after adding CAC to
our models is intriguing and may indicate that FH
reﬂects risk that is not proportional to the burden of
coronary atherosclerosis as indirectly measured by
calcium accumulation. FH may select heritable
FIGURE 2 HRs for Incident CHD
Patients are stratiﬁed by FH in pre-speciﬁed subgroups. Young ¼ age #45
years in men, #55 years in women; older ¼ age >45 years in men, >55 years
in women. *Adjusted for sex, systolic blood pressure, total cholesterol (TC)
and high-density lipoprotein cholesterol (HDL-C), smoking status, diabetes,
antihypertensive drug and statin use, and CAC score. †Adjusted for age, sex,
systolic blood pressure, TC, HDL-C, smoking status, presence of diabetes, and
antihypertensive drug and statin use. ††Adjusted for age, sex, and CAC score.
§Adjusted for age, sex, systolic blood pressure, presence of diabetes, TC,
HDL-C, smoking status, antihypertensive drug and statin use, and CAC score.
FRS ¼ Framingham risk score (expressed as 10-year risk for coronary artery
disease events); HR ¼ hazard ratio; RF ¼ risk factor(s); other abbreviations as
in Figure 1.
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684factors reﬂecting inﬂammatory and coagulation
pathways, resulting in rupture-prone plaques that are
not completely reﬂected by one’s extent of coronary
atherosclerosis (26). In addition, calciﬁed plaques
in the coronary arteries comprise only a small pro-
portion of the total plaque burden. Genetic factors,
particularly in younger populations that are less
prone to calciﬁcation, may operate to increase the risk
for CHD events in ways that are not proportional to
calciﬁed coronary plaque burden. In fact, 1 study
involving patients undergoing coronary CT angiog-
raphy revealed that FH was associated with the
extent of noncalciﬁed coronary plaque independent
of the quantity of calciﬁed plaque (27).Patients with FH have a signiﬁcantly higher life-
time risk for CHD events and are often referred for
CAC testing to better discern their individual risks
(28). Our results suggest that FH and CAC may be
additive in their information such that those with
both characteristics are at particularly high short-
term risk, with nearly double the risk of those with
CAC alone. Interestingly, a recent study demon-
strated that among patients with marked coronary
calciﬁcation, FH may identify those who would most
beneﬁt from aggressive medical therapy (29). In a
post-hoc analysis of the St. Francis Heart Study, in
which patients with CAC above the 80th percentile
were randomized to atorvastatin 20 mg or placebo,
Mulders et al. (29) showed that the subgroup with
FH beneﬁtted from statin therapy (HR cardiovascu-
lar events: 0.55; 95% CI: 0.31 to 0.97; p ¼ 0.04),
whereas there was no statistical reduction in pa-
tients without FH.
The trend toward higher adjusted CHD event rates
associated with FH among patients without coro-
nary calciﬁcation has potential clinical implications
because these patients are thought to be at very low
risk (6). Although the absolute short-term risk for
CHD was still low in this young group, the presence
of FH may signify the potential for future progression
to a more aggressive phenotype and high lifetime
risk for CHD (28). Indeed, participants with FH
despite the absence of CAC had higher prevalences of
hypertension, diabetes, and metabolic syndrome, as
well as greater adiposity and left ventricular mass.
The improvement in risk classiﬁcation evidenced
by a modest change in c statistic and the signiﬁcant
category-free NRI support the clinical relevance of
FH. This modest effect of FH on measurements of
discrimination is consistent with data from prior
studies (2). In a recent study by Yeboah et al. (3),
participants in the intermediate-risk category were
exclusively evaluated. Compared with other novel
risk markers, CAC and FH were the strongest pre-
dictors of CHD, and the addition of FH to a model
containing TRF resulted in a signiﬁcant improvement
in the c statistic (from 0.62 to 0.68; p ¼ 0.001) and a
category-based NRI of 0.16. The large improvement
in c statistic in this particular study was probably
facilitated by the fairly low performance of the base-
line model, unlike the high baseline c statistic for the
TRF model (0.85) in our cohort.
The implications of our ﬁndings for the interpre-
tation of CAC measurement in patients with FH are
several-fold. The presence of FH is associated with a
higher CHD risk, regardless of CAC results. In addi-
tion, patients who have both FH and CAC appear to
be at particularly high risk and may require a lower
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685threshold for implementation of preventive thera-
pies. Furthermore, the absence of CAC may not
completely abrogate the increment in CHD risk in
those with FH, and these patients may beneﬁt from
intensiﬁed life-style interventions as well as more
vigilant surveillance for the development of
risk factors. Finally, consistent with our prior report,
FH may be particularly informative in younger pa-
tients (8).
STUDY LIMITATIONS. The relatively young age of our
cohort (mean age at time of CAC scanning: 44 years)
limits generalizability to older patients. It is known
that CAC is more prevalent at older ages and may be
more reﬂective of a longer exposure to FH. However,
even in our subgroup analysis of older participants,
adjusting for CAC did not signiﬁcantly diminish the
association between FH and CHD. We also had a
limited number of clinical CHD events and thus
limited power to detect potentially clinically mean-
ingful differences in particularly informative subsets,
such as patients without CAC and those in the high
Framingham risk category. The DHS was designed as
a population-based cohort with the goal of improving
the mechanistic understanding and prevention of
cardiovascular disease but not speciﬁcally to assess
the association between FH, CAC, and CHD. Family
history was therefore obtained through participant
reporting, which is subject to misclassiﬁcation and
recall bias. This, however, is the norm in the ﬁeld of
cardiovascular epidemiology and consists of the same
family history information available to practicing
clinicians. Furthermore, reports from the FamilyHeart Study and the Newcastle Family History Study
suggest that self-reported parental history has a
sensitivity >80% and speciﬁcity approaching 90%,
and that any misclassiﬁcation of family history would
bias associations toward the null (30–32). Therefore,
we believe that our data represent a conservative
estimate of the association between FH and CHD
and its additive value to CAC. Finally, age deﬁnitions
for FH and premature FH were determined by the
original DHS questionnaire and differ from current
guidelines (5). Prior studies, however, suggest that
FH remains predictive of CHD across a wide range of
parental ages (33).
CONCLUSIONS
FH was associated with incident CHD independent of
baseline CAC, and its predictive value was not atten-
uated by CAC measurements. FH and CAC seem to be
additive such that patients with both factors are at
particularly high risk. In the subgroup of patients
without signiﬁcant coronary calciﬁcation, FH may
still be informative by identifying patients at higher
relative risk and selecting a group with a more
unfavorable cardiometabolic proﬁle. FH and CAC
provide complementary information for CHD risk
assessment.
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